Fig. 1From: A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapyThe Kaplan-Meier curves for (a) progression-free survival (PFS) and (b) overall survival (OS) among the control group and the groups with the worst and best responses to first-line targeted therapyBack to article page